Correction: Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling (The Journal of Allergy and Clinical Immunology (2017) 140(2) (543–552.e5) (S0091674916314385)(10.1016/j.jaci.2016.10.031));Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling

Journal of Allergy and Clinical Immunology

Volumn 140, Issue 2, 2017, Pages 543-552.e5

  Melki, Isabelle ^a,b,c,d   Rose, Yoann ^a,b   Uggenti, Carolina ^a,b   Van Eyck, Lien ^a,b,l   Frémond, Marie Louise ^a,b,d   Kitabayashi, Naoki ^a,b   Rice, Gillian I ^e   Jenkinson, Emma M ^e   Boulai, Anaïs ^a,b   Jeremiah, Nadia ^a,b   Gattorno, Marco ^f   Volpi, Sefano ^f   Sacco, Olivero ^g   Terheggen Lagro, Suzanne W J ^h   Tiddens, Harm A W M ^i,j   Meyts, Isabelle ^k,l   Morren, Marie Anne ^k   De Haes, Petra ^k,l   Wouters, Carine ^d,k,l   Legius, Eric ^k,l   Corveleyn, Anniek ^k   Rieux Laucat, Frederic ^a,b   Bodemer, Christine ^b,d   Callebaut, Isabelle ^m   Rodero, Mathieu P ^a,b   Crow, Yanick J ^a,b,e   more..

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f Division of Ophthalmology   (Italy)

^g G GASLINI INSTITUTE   (Italy)

^h EMMA CHILDREN S HOSPITAL   (Netherlands)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l UNIVERSITY OF LEUVEN   (Belgium)

^m SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

interferon; Stimulator of interferon genes (STING); STING associated vasculopathy with onset in infancy; TMEM173; type I interferonopathy

Indexed keywords

ACETYLSALICYLIC ACID; AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; BETA INTERFERON; CD19 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERFERON; INTERFERON REGULATORY FACTOR 3; JANUS KINASE 1; JANUS KINASE 2; MEMBRANE PROTEIN; METHOTREXATE; NIFEDIPINE; PENTOXIFYLLINE; RUXOLITINIB; STAT1 PROTEIN; STEROID; STIMULATOR OF INTERFERON GENE PROTEIN; TANK BINDING KINASE 1; TRANSMEMBRANE PROTEIN 173; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; MPYS PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN;

ACROCYANOSIS; ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOINFLAMMATORY DISEASE; BACTERIAL INFECTION; CASE REPORT; CHILD; COLD; COMPUTER ASSISTED TOMOGRAPHY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; ERYTHEMA; EX VIVO STUDY; EXERCISE TOLERANCE; FAILURE TO THRIVE; FEEDING DIFFICULTY; FEMALE; FIBROSING ALVEOLITIS; FLOW CYTOMETRY; GAIN OF FUNCTION MUTATION; GASTROSTOMY; GENETIC ANALYSIS; GRANULOMATOUS HEPATITIS; HEPATOMEGALY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFLAMMATION; INTERSTITIAL LUNG DISEASE; INTRAUTERINE GROWTH RETARDATION; LIVER BIOPSY; MALE; OXYGEN THERAPY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RECURRENT INFECTION; RESPIRATORY DISTRESS; SCHOOL CHILD; SEPTICEMIA; SKIN BIOPSY; SKIN DEFECT; STIMULATOR OF INTERFERON GENE ASSOCIATED VASCULOPATHY; TELANGIECTASIA; UPPER RESPIRATORY TRACT INFECTION; UPREGULATION; VASCULAR DISEASE; WEIGHT GAIN; GENETICS; HEK293 CELL LINE; METABOLISM; MUTATION; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; CHILD; FEMALE; HEK293 CELLS; HUMANS; INFLAMMATION; INTERFERON TYPE I; MALE; MEMBRANE PROTEINS; MUTATION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 85009253011     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2017.10.002     Document Type: Erratum

References (33)

1. Liu, Y., Jesus, A.A., Marrero, B., Yang, D., Ramsey, S.E., Montealegre Sanchez, G.A., et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 371 (2014), 507–518.
2. Jeremiah, N., Neven, B., Gentili, M., Callebaut, I., Maschalidi, S., Stolzenberg, M.-C., et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest 124 (2014), 5516–5520.
3. Munoz, J., Rodière, M., Jeremiah, N., Rieux-Laucat, F., Oojageer, A., Rice, G.I., et al. Stimulator of interferon genes-associated vasculopathy with onset in infancy: a mimic of childhood granulomatosis with polyangiitis. JAMA Dermatol 151 (2015), 872–877.
4. Omoyinmi, E., Melo Gomes, S., Nanthapisal, S., Woo, P., Standing, A., Eleftheriou, D., et al. Stimulator of interferon genes-associated vasculitis of infancy. Arthritis Rheumatol, 67, 2015, 808.
5. Frémond, M.-L., Rodero, M.P., Jeremiah, N., Belot, A., Jeziorski, E., Duffy, D., et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in three children. J Allergy Clin Immunol 138 (2016), 1752–1755.
6. König, N., Fiehn, C., Wolf, C., Schuster, M., Costa, E.C., Tüngler, V., et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis, 2016 [Epub ahead of print].
7. Picard, C., Thouvenin, G., Kannengiesser, C., Dubus, J.-C., Jeremiah, N., Rieux-Laucat, F., et al. Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 mutation). Chest 150 (2016), e65–e71.
8. Clarke, S.L.N., Pellowe, E.J., de Jesus, A.A., Goldbach-Mansky, R., Hilliard, T.N., Ramanan, A.V., Interstitial lung disease caused by STING-associated vasculopathy with onset in infancy. Am J Respir Crit Care Med 194 (2016), 639–642.
9. Crow, Y.J., Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci 1238 (2011), 91–98.
10. Crow, Y.J., Casanova, J.-L., STING-associated vasculopathy with onset in infancy–a new interferonopathy. N Engl J Med 371 (2014), 568–571.
11. Ishikawa, H., Barber, G.N., STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455 (2008), 674–678.
12. Burdette, D.L., Monroe, K.M., Sotelo-Troha, K., Iwig, J.S., Eckert, B., Hyodo, M., et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 478 (2011), 515–518.
13. Barber, G.N., STING: infection, inflammation and cancer. Nat Rev Immunol 15 (2015), 760–770.
14. Zhang, X., Shi, H., Wu, J., Zhang, X., Sun, L., Chen, C., et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell 51 (2013), 226–235.
15. Dobbs, N., Burnaevskiy, N., Chen, D., Gonugunta, V.K., Alto, N.M., Yan, N., STING activation by translocation from the ER is associated with infection and autoinflammatory disease. Cell Host Microbe 18 (2015), 157–168.
16. Liu, S., Cai, X., Wu, J., Cong, Q., Chen, X., Li, T., et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science, 347, 2015, aaa2630.
17. Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T., et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536 (2016), 285–291.
18. Gentili, M., Kowal, J., Tkach, M., Satoh, T., Lahaye, X., Conrad, C., et al. Transmission of innate immune signaling by packaging of cGAMP in viral particles. Science 349 (2015), 1232–1236.
19. Yi, G., Brendel, V.P., Shu, C., Li, P., Palanathan, S., Cheng Kao, C., Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLoS One, 8, 2013, e77846.
20. Katoh, K., Standley, D.M., MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30 (2013), 772–780.
21. Robert, X., Gouet, P., Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res 42 (2014), W320–W324.
22. Ouyang, S., Song, X., Wang, Y., Ru, H., Shaw, N., Jiang, Y., et al. Structural analysis of the STING adaptor protein reveals a hydrophobic dimer interface and mode of cyclic di-GMP binding. Immunity 36 (2012), 1073–1086.
23. Konno, H., Konno, K., Barber, G.N., Cyclic dinucleotides triggerULK1(ATG1) phosphorylation of STING to prevent sustained innate immune signaling. Cell 155 (2013), 688–698.
24. Holm, C.K., Jensen, S.B., Jakobsen, M.R., Cheshenko, N., Horan, K.A., Moeller, H.B., et al. Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat Immunol 13 (2012), 737–743.
25. Olagnier, D., Hiscott, J., Breaking the barrier: membrane fusion triggers innate antiviral immunity. Nat Immunol 13 (2012), 713–715.
26. Holm, C.K., Rahbek, S.H., Gad, H.H., Bak, R.O., Jakobsen, M.R., Jiang, Z., et al. Influenza A virus targets a cGAS-independent STING pathway that controls enveloped RNA viruses. Nat Commun, 7, 2016, 10680.
27. Tanaka, Y., Chen, Z.J., STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal, 5, 2012, ra20.
28. Tang, E.D., Wang, C.-Y., Single amino acid change in STING leads to constitutive active signaling. PLoS One, 10, 2015, e0120090.
29. Shu, C., Yi, G., Watts, T., Kao, C.C., Li, P., Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune system. Nat Struct Mol Biol 19 (2012), 722–724.
30. Mukai, K., Konno, H., Akiba, T., Uemura, T., Waguri, S., Kobayashi, T., et al. Activation of STING requires palmitoylation at the Golgi. Nat Commun, 7, 2016, 11932.
31. Hasan, M., Dobbs, N., Khan, S., White, M.A., Wakeland, E.K., Li, Q.-Z., et al. Cutting edge: inhibiting TBK1 by compound II ameliorates autoimmune disease in mice. J Immunol 195 (2015), 4573–4577.
32. Hasan, M., Yan, N., Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies. Pharmacol Res 111 (2016), 336–342.
33. Shigemoto, T., Kageyama, M., Hirai, R., Zheng, J., Yoneyama, M., Fujita, T., Identification of loss of function mutations in human genes encoding RIG-I and MDA5: implications for resistance to type I diabetes. J Biol Chem 284 (2009), 13348–13354.